Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas
Latest Information Update: 18 Apr 2022
Price :
$35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Haemangioendothelioma; Haemangiosarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms MoST Addendum 5
- 09 Mar 2022 Status changed from active, no longer recruiting to completed.
- 10 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2020 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.